Pembrolizumab
approved for first-line treatment of head and neck squamous cell carcinoma
Reuters (6/11, Babu) reports that “Merck & Co Inc said
on Tuesday its blockbuster cancer drug Keytruda [pembrolizumab] won approval
from the” FDA “to treat a type of head and neck cancer.” The medication “was
approved for use as a monotherapy, as well as in combination with a common
chemotherapy regimen, to treat previously untreated patients with head and neck
squamous cell carcinoma, Merck said.”
